Duke at AHA: Sunday, November 14, 2010

Duke Heart Center brings you highlights of today's news and commentary from the AHA’s annual Scientific Sessions occurring in Chicago.

Late Breaking Research Session:

Duke led research answers controversial drug safety questions in world's largest heart failure study.

Read more about ASCEND-HF (PDF)

Video: Discussion with study investigators, Drs. Robert Califf, Christopher O'Connor, Adrian Hernandez and Randy Starling
Video: Clyde Yancy, MD, immediate past president of the AHA, provides a historical perspective & implications for patients.

Late Breaking Research Session:

In a trial that was suspended early and could change treatment guidelines, more details are revealed about eplerenone's ability to reduce death or hospitalization in NYHA class II heart failure.

Read more about EMPHASIS HF (PDF)

Late Breaking Research Session & New England Journal Publication:

New findings explore optimizing outcomes in mild to moderate heart failure and ask: is there a role for cardiac resynchronization therapy (CRT)?

Read more about RAFT (PDF)

Christopher O'Connor, MD, Director of the Duke Heart Center, and fellow Zubin Eapen discuss the hot topics and what is anticipated at this year's meeting.

Watch video

Lifetime Achievement Award:

For the second year in a row, a Duke researcher is being honored by the American Heart Association for lifetime achievements that have advanced the field of cardiovascular research. Victor J. Dzau, MD, chancellor for health affairs at Duke University and CEO, Duke University Health System, has been awarded the prestigious 2010 Research Achievement Award of the American Heart Association.

Watch videos of Dr. Dzau receiving his award and get live updates from AHA by visiting the Duke fellows’ blog at https://www.dukecardiologyfellows.org/dcfblog/

Want more news and views from AHA? Visit http://www.dukehealth.org/heart_center/health_library/news/duke-heart-center-at-american-heart-associations-scientific-sessions each day to see the latest videos and gain context, discussion, opinion about what the new data mean for patients and practice.

end fo content area